Nick Pizzie sold $2.3M of AXSM
Chief Financial Officer at Axsome Therapeutics, Inc.. 12,000 shares at an average of $187.92, traded Jan 22, 2026, filed Jan 23, 2026.
Score components
- +22RoleCFO
- +25Trade size$2.3M at market
- +5Share of holdings soldSold 22% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-26-021378, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 22, 2026 | MOption exercise Common Stock10b5-1 | +12,000 | $3.50 | $42k | 54,588 | Jan 23, 2026 |
| Jan 22, 2026 | SOpen-market sale Common Stock10b5-1 | -12,000 | $187.92 | $2.3M | 42,588 | Jan 23, 2026 |
| Jan 22, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -12,000 | $0.00 | $0 | 105,000 | Jan 23, 2026 |
Related signals
Other insiders at Axsome Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 30Weak | Axsome Therapeutics, Inc. | Mark L. Jacobson Chief Operating Officer | $2.1M 10,000 shares | -100% | |
| 38Weak | Axsome Therapeutics, Inc. | Mark L. Jacobson Chief Operating Officer | $5.7M 35,378 shares | -100% | |
| 38Weak | Axsome Therapeutics, Inc. | Mark Coleman director | $4.0M 25,000 shares | -35% | |
| 50Moderate | Axsome Therapeutics, Inc. | Herriot Tabuteau Chief Executive Officer | $6.0M 32,410 shares | -82% | |
| 40Moderate | Axsome Therapeutics, Inc. | Ari Maizel Chief Commercial Officer | $1.4M 7,500 shares | -100% | |
| 43Moderate | Axsome Therapeutics, Inc. | Herriot Tabuteau Chief Executive Officer | $24M 139,414 shares | -162% | |
| 33Weak | Axsome Therapeutics, Inc. | Mark E Saad director | $6.2M 37,577 shares | -231% | |
| 35Weak | Axsome Therapeutics, Inc. | Herriot Tabuteau Chief Executive Officer | $12M 79,973 shares | -142% | |
| 35Weak | Axsome Therapeutics, Inc. | Herriot Tabuteau Chief Executive Officer | $22M 163,939 shares | -166% | |
| 43Moderate | Axsome Therapeutics, Inc. | Herriot Tabuteau Chief Executive Officer | $5.4M 45,384 shares | -172% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.